Recursion(US:RXRX) ZACKS·2025-10-29 15:07Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Recursion Pharmaceuticals due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Company Summary - Recursion Pharmaceuticals is expected to report a quarterly loss of $0.38 per share, reflecting an 11.8% decrease year-over-year [3]. - Projected revenues for the quarter are $17.45 million, down 33.1% from the same quarter last year [3]. - The consensus EPS estimate has been revised down by 4.27% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Recursion Pharmaceuticals is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +18.42% [11]. - Despite the positive Earnings ESP, the stock has a Zacks Rank of 4, complicating predictions of an earnings beat [11]. - The company has not surpassed consensus EPS estimates in the last four quarters, with a previous surprise of -17.14% [12][13]. Industry Context - Niagen Bioscience, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report an EPS of $0.02, unchanged from the previous year, with revenues projected at $31.3 million, up 22.4% [17]. - Niagen Bioscience has an Earnings ESP of -33.33% and a Zacks Rank of 4, making it difficult to predict an earnings beat [19].